News

Dr. Reddy`s Laboratories announced that the U.S. Food and Drug Administration (FDA) has approved its rituximab biosimilar, a biosimilar to Rituxan� (rituximab), for the U.S. market. The approval further strengthens Dr. Reddy`s growing global biosimilars portfolio and advances its biosimilars business in the United States. The product was developed, manufactured and submitted for approval by Dr. Reddy`s Laboratories. The approval follows the successful recent Pre-License Inspection (PLI) conducted by the U.S. FDA at the Company`s biologics manufacturing facility in Bachupally, Hyderabad, and reflects the company`s capabilities in bringing complex biologic medicines to highly regulated markets and its long-standing commitment to biosimilars. Under a commercialization agreement, Fresenius Kabi holds the exclusive rights to commercialize the product in the United States, one of the world`s most important pharmaceutical markets.

Net profit of Dr Reddy`s Laboratories declined 68.67% to Rs 444.30 crore in the quarter ended June 2026 as against Rs 1418.10 crore during the previous quarter ended June 2025. Sales declined 5.56% to Rs 8070.50 crore in the quarter ended June 2026 as against Rs 8545.20 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales8070.508545.20 -6 OPM %10.6525.44 - PBDT1089.902381.10 -54 PBT553.301905.00 -71 NP444.301418.10 -69 Powered by Capital Market - Live News

The board of Dr Reddys Laboratories at its meeting held on 22 July 2026 has appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel of the Company effective 22 July 2026.

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 22 July 2026.

Dr Reddys Laboratories has allotted 6,730 equity shares under ESOP on 19 June 2026. Post allotment, the paid up equity share capital has increased to 83,46,76,800 equity shares of Re 1 each.